SLC5A2 and hydrops fetalis: The combined results of this meta-analysis indicated that the experimental group treated with SGLT-2 inhibitors experienced a 23% reduced risk of cardiovascular death or hospitalization for HF, a 19% reduced risk of cardiovascular death, and a 9% reduced risk of all-cause mortality.